Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib mesylate tablets with chemoradiotherapy in first-line treatment of advanced esophageal squamous cell carcinoma (real-world study)
ChiCTR2100045471Phase 4Recruiting
- Sponsor
- Yejishan Hospital of Wannan Medical College
- Start
- Apr 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yejishan Hospital of Wannan Medical College. Primary endpoint: Progression-free survival. Started Apr 2021; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100045471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045471.